Correction: scFv-based biologics in diabetes: from therapeutic potential to clinical prospects - Report - MDSpire

Correction: scFv-based biologics in diabetes: from therapeutic potential to clinical prospects

  • By

  • Shikun Ge

  • Luoxuan Wang

  • Yichen Huang

  • Huaizu Guo

  • Fuyao Wei

  • Pan Li

  • Siyuan Li

  • Qian Liu

  • Jin Xu

  • Yilei Xiao

  • Alberto Carlos Piress Dias

  • Lusha Ji

  • July 13, 2026

Share

Correction: scFv-based Therapeutics for Diabetes: Evaluating Their Potential

Overview

This correction addresses inaccuracies in author affiliations and conflict of interest statements in the article on scFv-based therapeutics for diabetes.

Background

The prevalence of diabetes mellitus is increasing globally. Accurate representation of authorship and affiliations is crucial for maintaining the integrity of scientific communication.

Data Highlights

No numerical or trial data is presented in the correction article.

Key Findings

  • Corrections were made to multiple author affiliations to reflect accurate institutional associations.
  • The corresponding author was corrected from Shikun Ge to Lusha Ji.
  • The conflict of interest statement was updated to clarify employment and potential conflicts.
  • A reference citation was corrected for accuracy in authorship and publication details.

Clinical Implications

The corrections made in author affiliations and conflict of interest disclosures are documented.

Conclusion

This article presents corrections to author affiliations and conflict of interest statements.

Related Resources & Content

  1. Ge S, Wang L, Huang Y, et al., Front. Immunol, 2026 -- Correction: scFv-based Therapeutics for Diabetes
  2. The Journal of Clinical Endocrinology & Metabolism — Correspondence from Papadimitriou: "Advancing Beyond Stages: Assessing Individualized Time-Dependent Risk for Type 1 Diabetes
  3. The Journal of Clinical Endocrinology & Metabolism — Clinical Research in Diabetes: The Role of Biomarkers, Proteoforms, and Mass Spectrometry Techniques
  4. The Journal of Clinical Endocrinology & Metabolism — Reply to Hao and Xue's Letter to the Editor: “Characteristics of Checkpoint Inhibitor-Induced Autoimmune Diabetes Mellitus Include C-Peptide Depletion and Pancreatic Atrophy”
  5. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
  6. Immunomodulatory interventions in type 1 diabetes: a systematic review and meta-analysis revealing paradoxical dissociation between beta-cell preservation and glycemic control - PubMed
  7. Frontiers | scFv-based biologics in diabetes: from therapeutic potential to clinical prospects

Original Source(s)

Correction: scFv-based biologics in diabetes: from therapeutic potential to clinical prospects

  • by Shikun Ge, Luoxuan Wang, Yichen Huang, Huaizu Guo, Fuyao Wei, Pan Li, Siyuan Li, Qian Liu, Jin Xu, Yilei Xiao, Alberto Carlos Piress Dias, Lusha Ji

  • July 13, 2026

Related Content

Stage-dependent alterations of Sonoclot coagulation profiles across the spectrum of diabetic peripheral neuropathy

Nontraditional lipid and lipid-inflammatory parameters for risk stratification of abnormal glucose metabolism: a cross-sectional study in Chinese adults

Promoting Problem-Solving Among Low-Income Adults With Type 2 Diabetes: Cluster-Randomized Controlled Trial of a Mobile Health Intervention With SMS Text Messaging (Mobile Diabetes Detective)